source
- Precision Neuroscience raises $250M in Series D to expand brain-computer interface programPrecision Neurosciences announced a $250 million Series D financing round that was oversubscribed. The capital injection follows previous rounds that have brought the company’s total funding to $43…
- Ultragenyx gains FDA approval for Fayuvi, a Sanfilippo syndrome A therapy, easing impact of recent Angelman setbackUltragenyx announced that the FDA has approved its drug Fayuvi for treating Sanfilippo syndrome type A, a rare neurodegenerative condition affecting children. The approval marks the company's first…